S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
NASDAQ:CTMX

CytomX Therapeutics (CTMX) Stock Price, News & Analysis

$1.86
-0.11 (-5.58%)
(As of 04:00 PM ET)
Today's Range
$1.86
$1.99
50-Day Range
$1.41
$2.74
52-Week Range
$1.04
$2.86
Volume
335,827 shs
Average Volume
872,809 shs
Market Capitalization
$125.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.10

CytomX Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
62.9% Upside
$3.10 Price Target
Short Interest
Healthy
4.90% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.74
Upright™ Environmental Score
News Sentiment
1.43mentions of CytomX Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$73,200 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.21) to ($0.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.36 out of 5 stars

Medical Sector

126th out of 930 stocks

Pharmaceutical Preparations Industry

45th out of 427 stocks

CTMX stock logo

About CytomX Therapeutics Stock (NASDAQ:CTMX)

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

CTMX Stock Price History

CTMX Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
J.P. Morgan Keeps Their Sell Rating on CytomX Therapeutics (CTMX)
Recap: CytomX Therapeutics Q4 Earnings
CytomX Therapeutics's Earnings Outlook
BMY Oct 2024 45.000 put
BMY Apr 2024 52.000 put
BMY Aug 2024 60.000 call
See More Headlines
Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/11/2024
Today
4/16/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CTMX
Employees
120
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.10
High Stock Price Target
$3.19
Low Stock Price Target
$3.00
Potential Upside/Downside
+62.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-570,000.00
Pretax Margin
3.28%

Debt

Sales & Book Value

Annual Sales
$101.21 million
Book Value
($0.71) per share

Miscellaneous

Free Float
62,991,000
Market Cap
$128.69 million
Optionable
Optionable
Beta
1.01
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

CTMX Stock Analysis - Frequently Asked Questions

Should I buy or sell CytomX Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTMX shares.
View CTMX analyst ratings
or view top-rated stocks.

What is CytomX Therapeutics' stock price target for 2024?

2 brokerages have issued twelve-month price objectives for CytomX Therapeutics' shares. Their CTMX share price targets range from $3.00 to $3.19. On average, they predict the company's share price to reach $3.10 in the next twelve months. This suggests a possible upside of 62.9% from the stock's current price.
View analysts price targets for CTMX
or view top-rated stocks among Wall Street analysts.

How have CTMX shares performed in 2024?

CytomX Therapeutics' stock was trading at $1.55 at the start of the year. Since then, CTMX stock has increased by 22.6% and is now trading at $1.90.
View the best growth stocks for 2024 here
.

Are investors shorting CytomX Therapeutics?

CytomX Therapeutics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 3,320,000 shares, a decline of 5.9% from the March 15th total of 3,530,000 shares. Based on an average trading volume of 864,800 shares, the days-to-cover ratio is presently 3.8 days.
View CytomX Therapeutics' Short Interest
.

When is CytomX Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CTMX earnings forecast
.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its earnings results on Monday, March, 11th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.01. The biotechnology company earned $26.61 million during the quarter, compared to the consensus estimate of $23.36 million.

What ETF holds CytomX Therapeutics' stock?

Formidable ETF holds 318,111 shares of CTMX stock, representing 1.80% of its portfolio.

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend.

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Congress Park Capital LLC (0.35%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Elaine V Jones, Jeffrey B Landau, Lloyd A Rowland, Marcia Belvin and Sean A Mccarthy.
View institutional ownership trends
.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTMX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners